Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - KalVista Pharmaceuticals ( NASDAQ:KALV ) , Metagenomi ( NASDAQ:MGX )
EMERYVILLE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Metagenomi, Inc. MGX ( the "Company" ) , a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to ...
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Apple ( NASDAQ:AAPL ) , Above Food Ingredients ( NASDAQ:ABVE )
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday. Shares of Ultragenyx Pharmaceutical Inc. RARE fell sharply in pre-market trading. Ultragenyx received a Complete Response Letter from the FDA for UX111 AAV gene therapy to treat Sanfilippo ...
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday - Abbott Laboratories ( NYSE:ABT ) , Danaher ( NYSE:DHR )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Evercore ISI Group slashed Danaher Corporation DHR price target from $230 to $226.
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday - Amber International ( NASDAQ:AMBR ) , Baidu ( NASDAQ:BIDU )
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of KalVista Pharmaceuticals, Inc. KALV rose sharply during Monday's session after the company announced it won FDA approval for EKTERLY. The U.S.
Why Is KalVista Pharmaceuticals Stock Soaring On Monday? - KalVista Pharma ( NASDAQ:KALV )
Ekterly approved by FDA as the first oral on-demand treatment for HAE in patients 12 and older. KONFIDENT-S trial showed a median 10-minute treatment time after HAE attack onset. Get ahead of Wall Street reactions-Benzinga Pro delivers signals, squawk, and news fast. Now 60% off this 4th of July.
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - DoubleVerify Hldgs ( NYSE:DV ) , Box ( NYSE:BOX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs analyst Paul Choi initiated coverage on Lantheus Holdings, Inc.
Super Micro Computer And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Innventure ( NASDAQ:INV ) , Innovex International ( NYSE:INVX )
U.S. stock futures were slightly higher this morning, with the Nasdaq futures gaining around 0.2% points on Monday. Shares of Super Micro Computer, Inc. SMCI fell sharply in today's pre-market trading following reports suggesting the company tapped Evercore to raise capital and is considering ...
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday - NVIDIA ( NASDAQ:NVDA )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for Adobe Inc. ADBE from $700 to $635.
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings.
KalVista Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating
KalVista Pharmaceuticals ( KALV ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Monday, rising from 69 to 82. X IBD's proprietary rating measures price action with a 1 ( worst ) to 99 ( best ) score.
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday - Citigroup ( NYSE:C )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for CrowdStrike Holdings, Inc. CRWD from $318 to $375.
Why Is KalVista Pharmaceuticals Stock Trading Lower Today? - KalVista Pharma ( NASDAQ:KALV )
KalVista Pharmaceuticals Inc KALV released results from the phase 3 KONFIDENT trial demonstrating statistically and clinically significant efficacy of sebetralstat as an oral on-demand therapy for hereditary angioedema ( HAE ) , a disorder characterized by recurrent episodes of severe swelling ( ...
Insiders Buying Monro And 3 Other Stocks - KalVista Pharma ( NASDAQ:KALV ) , Lee Enterprises ( NASDAQ:LEE )
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying - Cleveland-Cliffs ( NYSE:CLF ) , ArriVent BioPharma ( NASDAQ:AVBP )
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying - KalVista Pharma ( NASDAQ:KALV ) , FB Financial ( NYSE:FBK )
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
$230M Bet On Talos Energy? Check Out These 4 Stocks Insiders Are Buying - KalVista Pharma ( NASDAQ:KALV ) , Amrep ( NYSE:AXR )
Although U.S. stocks closed higher on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Insiders Buying Dorian LPG And 2 Other Stocks - Avadel Pharmaceuticals ( NASDAQ:AVDL ) , KalVista Pharma ( NASDAQ:KALV )
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks - KalVista Pharma ( NASDAQ:KALV ) , Avid Bioservices ( NASDAQ:CDMO )
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
$6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying - KalVista Pharma ( NASDAQ:KALV ) , NB Bancorp ( NASDAQ:NBBK )
Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Around $2.4M Bet On HighPeak Energy? Check Out These 4 Stocks Insiders Are Buying - HighPeak Energy ( NASDAQ:HPK ) , KalVista Pharma ( NASDAQ:KALV )
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
XORTX Welcomes New Member to the Board of Directors
CALGARY, Alberta, Jan. 02, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Mr. ...
Are Medical Stocks Lagging Amneal Pharmaceuticals ( AMRX ) This Year?
Here is how Amneal Pharmaceuticals (AMRX) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Cabaletta Bio ( CABA ) This Year?
Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.
Is it a Good Idea to Invest in KalVista ( KALV ) Stock Now?
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.
Here's Why You Should Invest in Alpine ( ALPN ) Stock Now
Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
Is KalVista Pharmaceuticals ( KALV ) Stock Outpacing Its Medical Peers This Year?
Here is how KalVista Pharmaceuticals, Inc. (KALV) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
KalVista ( KALV ) Surges 15% on Update From Angioedema Study
KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angioedema attacks. The stock rises 15% in response.
Wall Street Analysts See a 145.38% Upside in KalVista Pharmaceuticals, Inc. ( KALV ) : Can the Stock Really Move This High?
The consensus price target hints at a 145.4% upside potential for KalVista Pharmaceuticals, Inc. (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near ...
Here's Why You Should Invest in Larimar ( LRMR ) Stock Now
Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.
Here's Why You Can Add KalVista ( KALV ) Stock to Your Portfolio
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics
Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Rebounds in 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. ( KALV ) Could Surge 145.98%: Read This Before Placing a Bet
The consensus price target hints at a 146% upside potential for KalVista Pharmaceuticals, Inc. (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near ...
KalVista Pharmaceuticals, Inc. ( KALV ) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
KalVista Pharmaceuticals, Inc. (KALV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts See a 155.32% Upside in KalVista Pharmaceuticals, Inc. ( KALV ) : Can the Stock Really Move This High?
The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 155.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What Makes KalVista Pharmaceuticals, Inc. ( KALV ) a New Buy Stock
KalVista Pharmaceuticals, Inc. (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. ( KALV ) Could Surge 149.94%: Read This Before Placing a Bet
The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 149.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Gold Rises Over 1%; Elys Game Technology Shares Spike Higher - Acer Therapeutics ( NASDAQ:ACER ) , Elys Game Technology ( NASDAQ:ELYS )
U.S. stocks traded mixed toward the end of trading, with the Dow Jones trading slightly higher on Tuesday. The Dow traded up 0.10% to 33,237.71 while the NASDAQ fell 1.29% to 10,362.21. The S&P 500 also fell, dropping, 0.48% to 3,826.23. Check This Out: Top 5 Industrials Stocks That May Rally
Dow Rises 100 Points; Crude Oil Rises Over 1% - Acer Therapeutics ( NASDAQ:ACER ) , Elys Game Technology ( NASDAQ:ELYS )
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Tuesday. The Dow traded up 0.32% to 33,309.30 while the NASDAQ fell 0.81% to 10,413.00. The S&P 500 also fell, dropping, 0.16% to 3,838.62. Check This Out: Top 5 Industrials Stocks That May Rally
KalVista Pharma Rises; Offers To Sell Shares
KalVista Pharma Rises. Offers To Sell Shares ...
Will Pacira's ( PCRX ) Exparel Aid Growth Amid High Reliance?
Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.
KalVista Says Sebetralstat's Orally Disintegrating Formulation At Par With Film-Coated Version For HAE Attacks - KalVista Pharma ( NASDAQ:KALV )
KalVista Pharmaceuticals Inc KALV announced phase 1 data for an orally disintegrating tablet ( ODT ) formulation for its lead compound sebetralstat. Sebetralstat is currently being developed in the phase 3 KONFIDENT trial as a potential on-demand treatment for hereditary angioedema ( HAE ) ...
KalVista ( KALV ) Stock Continues to Decline: Here's Why
The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.
Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More
Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.
Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67% - HashiCorp ( NASDAQ:HCP ) , Invitation Homes ( NYSE:INVH )
HC Wainwright & Co. cut KalVista Pharmaceuticals, Inc. KALV price target from $48 to $16. KalVista Pharmaceuticals shares fell 1.8% to $5.06 in pre-market trading. Barclays cut IQVIA Holdings Inc. IQV price target from $235 to $215. IQVIA Holdings shares fell 0.3% to close at $192.49 on Wednesday.
This Analyst Boosts PT On Twitter? Plus Raymond James Predicts $1,750 For This Stock - M&T Bank ( NYSE:MTB ) , Chipotle Mexican Grill ( NYSE:CMG )
Raymond James raised the price target on Chipotle Mexican Grill, Inc. CMG from $1,700 to $1,750. Raymond James analyst Brian Vaccaro maintained an Outperform rating on the stock. Chipotle shares fell 0.8% to $1,524.02 in pre-market trading. Rosenblatt boosted the price target for Twitter, Inc.
